Personalis, Inc. (PSNL) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reflects strong quarterly growth, with a 26% increase in tests and a clear focus on expanding clinical volumes. The company's confidence in their ultrasensitive testing approach and strategic partnerships, along with improving gross margins and aggressive reimbursement strategies, indicate positive market sentiment. Despite some unclear responses in the Q&A, the overall outlook remains optimistic, especially with upcoming presentations at ASCO and a growing biopharma backlog. These factors suggest a positive stock price movement over the next two weeks.
Key Financial Performance
Clinical Test Volume Delivered more than 7,800 clinical tests in Q1 2026, representing a 26% sequential growth over Q4 2025 and a 258% year-over-year increase. The growth is attributed to the scaling of the NeXT Personal platform and increased adoption by physicians.
Revenue Total revenue for Q1 2026 was $15.5 million, a 25% decrease year-over-year. The decline is due to a planned transition from lower-margin legacy enterprise revenue to higher-margin clinical and biopharma MRD revenue, as well as the conclusion of Moderna's large Phase III trial enrollment.
Strategic Revenue Revenue from clinical testing and biopharma MRD adoption reached $4.5 million in Q1 2026, with strategic revenue expected to more than double year-over-year to $30 million to $32 million for the full year.
Biopharma Testing Services Revenue Biopharma testing services revenue was $11.2 million in Q1 2026, down from $13.6 million in Q1 2025. The decline is attributed to the expected decrease in revenue from Moderna due to the conclusion of their Phase III trial enrollment.
Biopharma MRD Revenue Biopharma MRD revenue was $3.1 million in Q1 2026, with a full-year goal of $20 million to $21 million. The growth is driven by the adoption of NeXT Personal for its ultrasensitivity and ability to detect cancer recurrence earlier than other technologies.
Clinical Revenue Clinical revenue was $1.4 million in Q1 2026, up from $0.3 million in Q1 2025. The increase is due to revenue from Medicare reimbursement coverages for breast and lung cancer surveillance.
Gross Margin Gross margin was 1.8% in Q1 2026, down from 35% in Q1 2025. The decline is intentional and temporary, driven by unreimbursed test costs and investments to gain market share. Margin improvement is expected as reimbursement coverage expands.
Operating Expenses Operating expenses were $32.4 million in Q1 2026, up from $24.9 million in Q1 2025. The increase is due to investments in commercial resources, studies for reimbursement, and technology development.
Net Loss Net loss for Q1 2026 was $30 million, compared to $15.8 million in Q1 2025. The increase is attributed to investments in market share growth, reimbursement studies, and technology innovation.
Cash Position Cash and short-term investments were $233.2 million at the end of Q1 2026, with approximately $28 million of cash used during the quarter, including $5 million of non-recurring incentive compensation.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
NeXT Personal: The product has disrupted the market with its ultrasensitive approach to tracking cancer recurrence using a simple blood draw. It detects a single fragment of tumor DNA in a background of 1 million, providing early detection and confidence in negative results.
Real-time variant tracker module: A new feature launched as a pilot to track how tumor biology changes in response to therapy, enabling proactive optimization of patient therapy.
MRD market opportunity: The market for tracking cancer in the blood is advancing towards a $20 billion opportunity, with Personalis positioned to capture significant share.
Clinical adoption: Achieved over 1,000 ordering physicians with a 98% retention rate. Annual volume estimate for 2026 is 43,000 to 45,000 tests.
Clinical test volume: Delivered over 7,800 clinical tests in Q1 2026, a 26% sequential growth and 258% year-over-year increase.
Revenue growth: Q1 revenue was $15.5 million, with strategic revenue from clinical testing and biopharma MRD adoption reaching $4.5 million. Full-year revenue guidance is $78-$80 million.
Biopharma MRD revenue: Achieved $3.1 million in Q1 and is on track for $20-$21 million for the full year, with significant scaling expected in the second half.
Reimbursement expansion: Submitted neoadjuvant breast cancer and pan-cancer submissions for coverage. Medicare coverage for breast and lung cancer surveillance tests already achieved.
Biopharma sector leadership: Growing pipeline with biopharma companies adopting NeXT Personal for its ultrasensitivity and ability to detect cancer recurrence earlier than other technologies.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Dependency on Moderna: The company experienced a planned decrease in revenue from Moderna due to the conclusion of a large Phase III trial enrollment. This dependency on a single customer for a significant portion of revenue poses a risk to financial stability.
Gross Margin Compression: Gross margin dropped significantly to 1.8% in Q1 2026 compared to 35% in the prior year. This is attributed to unreimbursed test costs and investments in gaining market share, which could impact profitability in the short term.
High Operating Expenses: Operating expenses increased to $32.4 million in Q1 2026 from $24.9 million in the prior year. This rise is due to investments in commercial resources, reimbursement studies, and technology development, which could strain financial resources.
Reimbursement Uncertainty: The company is awaiting reimbursement decisions for key submissions, including neoadjuvant breast cancer and pan-cancer monitoring. Delays or unfavorable outcomes could impact revenue growth and financial projections.
Cash Burn Rate: The company used approximately $28 million in cash during Q1 2026, with a projected annual cash usage of $100 million. This high burn rate could deplete cash reserves if revenue growth does not materialize as expected.
Market Competition: The company operates in a rapidly expanding MRD market expected to grow to $20 billion. Intense competition could challenge market share and pricing power.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: Personalis expects total company revenue for 2026 to be in the range of $78 million to $80 million, reflecting a 26% growth rate compared to 2025. Clinical revenue is projected to be $10 million to $11 million, while revenue from pharma tests and services is expected to be $55 million to $56 million. MRD revenue from these customers is anticipated to grow to $20 million to $21 million.
Clinical Test Volume: The company is confident in achieving its 2026 annual volume estimate of 43,000 to 45,000 clinical tests, driven by the adoption of NeXT Personal and partnerships like Tempus.
Gross Margin Outlook: Gross margin is expected to be in the range of 15% to 20% for 2026, with the lowest points in the first two quarters. Margin improvement is anticipated as reimbursement coverage expands.
Biopharma MRD Revenue: Biopharma MRD revenue is projected to reach $20 million to $21 million for 2026, with significant scaling expected in the second half of the year as larger projects commence.
Reimbursement Goals: Personalis is pursuing reimbursement for neoadjuvant breast cancer and pan-cancer immunotherapy monitoring. The company is confident in its data and expects coverage decisions to positively impact revenue and margins.
Market Opportunity: The MRD market is projected to grow to $20 billion or more, and Personalis aims to capture significant market share with its ultrasensitive technology.
Cash Usage and Investments: The company expects to use approximately $100 million in cash during 2026 to invest in market share growth, pivotal clinical studies, and technology innovation. With $233 million in cash reserves, Personalis is well-positioned to fund these initiatives.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What did the company observe in Q1 regarding competitive wins and volume growth?
A:The company achieved 26% growth quarter-over-quarter with 7,800 tests. They noted strong performance in the marketplace, particularly with their ultrasensitive capability. They also set an annual target of 43,000 to 45,000 clinical tests and focused on depth within existing clients, crossing 1,000 physicians ordering in the quarter.
Q:What guidance was provided for Q2 volume growth and onboarding new physicians?
A:The company expects physicians to adopt the technology at varying rates, with some ordering heavily from the start and others testing the service before increasing usage. They emphasized the opportunity to deepen usage across accounts and noted significant retention among accounts using NeXT Personal.
Q:How did lung and breast cancer volumes perform in Q1, and what is the status of IO monitoring?
A:Breast cancer volumes were around 20%, while lung cancer volumes were closer to 15%. IO monitoring volumes remained consistent, and the company expressed confidence in progress toward IO coverage, citing positive interactions and strong evidence.
Q:What can be expected at the upcoming ASCO conference?
A:The company plans to present more colorectal cancer data and expand into additional cancer types. They highlighted recent data from AACR, including results from 15,000 real-world patients and new product extensions like the real-time barrier tracker.
Q:How does the company view the competition between tumor-informed and tumor-naive tests?
A:The company believes the tumor-informed approach will remain dominant due to its superior sensitivity, which is highly valued by physicians. They emphasized that sensitivity is key in MRD testing.
Q:What is the outlook for gross margins and the strategy for reimbursed indications?
A:Gross margins are expected to improve in the second half of the year, with a full-year target of 15% to 20%. The company is not disincentivizing non-reimbursed tests but is focusing on growing reimbursed indications while maintaining service for all cancer types.
Q:What is the significance of the 1,000 ordering physicians in Q1?
A:The 1,000 physicians represent those who ordered tests during the quarter, not cumulatively. Most have some experience with MRD testing, and the company sees significant market growth driven by the ultrasensitive approach.
Q:What is the status of the biopharma MRD backlog and its impact on revenue?
A:The biopharma MRD backlog continues to grow, with a mix of retrospective and prospective projects. The company focuses on converting backlog within 12 months to revenue and sees strong demand for their ultrasensitive tests.
Q:What is the company's perspective on the ultrasensitive approach versus first-generation approaches?
A:The company sees increasing recognition of the importance of ultrasensitivity in MRD testing. They believe their approach provides critical benefits for patients, such as early detection of cancer recurrence and greater confidence in being cancer-free.
Q:What is the updated guidance for molecular volumes and the strategy for growth?
A:The company reaffirmed its guidance of 43,000 to 45,000 tests for the year, emphasizing disciplined growth and collaboration with their partner, Tempus. They aim to manage resources responsibly while pursuing their MRD strategy.
Q:What is the company's approach to MolDX submissions and reimbursement timelines?
A:The company noted that MolDX submissions typically have a 60-day turnaround for responses. They acknowledged variability in the process but expressed confidence in their progress and the strength of their evidence.
Q:What is the company's strategy for growing reimbursed indications?
A:The company aims to push more aggressively into reimbursed indications like breast and lung cancer while continuing to serve all cancer types. They see reimbursement as a key driver for growth and margin improvement.
Q:How does the company view its partnership with Tempus and the division of test volumes?
A:The company works synergistically with Tempus, leveraging their infrastructure and comprehensive product offerings. Tempus accounts for over 80% of test volumes, while the internal team focuses on complementary efforts.
Q:Review of Unclear Management Responses
A:Management avoided providing specific timelines or quantitative details for certain aspects, such as the exact timeline for reimbursement approvals (e.g., MolDX submissions) and the precise segmentation of the 1,000 ordering physicians. Additionally, responses about the growth of reimbursed versus non-reimbursed indications and the division of test volumes between the company and Tempus lacked detailed clarity.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Biopharma company
DNA
adoption
approach
biology tumor
biopharma MRD
cancer blood
cancer patient
collaborator Personal
confidence
detection
engine
evidence
immunotherapy
momentum
month
oncologist
physician
pillar
platform
point
power
precision
recurrence
response therapy
result website
submission
surgery
test
testing
track
trial
tumor response
variant
win MRD
PSNL Transcript
Personalis, Inc. (PSNL) Q1 2026 Earnings Call Transcript
Positive5-8
The earnings call summary reflects strong quarterly growth, with a 26% increase in tests and a clear focus on expanding clinical volumes. The company's confidence in their ultrasensitive testing approach and strategic partnerships, along with improving gross margins and aggressive reimbursement strategies, indicate positive market sentiment. Despite some unclear responses in the Q&A, the overall outlook remains optimistic, especially with upcoming presentations at ASCO and a growing biopharma backlog. These factors suggest a positive stock price movement over the next two weeks.
Personalis, Inc. (PSNL) Q4 2025 Earnings Call Transcript
Unknown2-26
Despite some operational improvements, the earnings call highlighted significant challenges, including a 15% revenue decline and reduced gross margins. Although net loss and cash flow improved, the revised revenue guidance and uncertainties around reimbursement decisions and collaborations present risks. These factors, combined with the absence of positive new developments or partnerships, suggest a negative sentiment overall.
Personalis, Inc. (PSNL) Q3 2025 Earnings Call Transcript
Unknown11-4
The earnings call highlights several challenges: reduced revenue guidance, logistical delays, and increased expenses. Despite positive developments like new customer onboarding and potential Medicare reimbursement, the lowered guidance and uncertainties in timelines overshadow the positives. The Q&A session reveals cautious management responses and possible revenue delays into Q1. These factors, combined with increased cash usage and reduced gross margin projections, suggest a negative market reaction in the short term, likely leading to a stock price decline of -2% to -8%.
Personalis, Inc. (PSNL) Q2 2025 Earnings Call Transcript
Positive8-5
The earnings call summary and Q&A indicate strong growth in MRD products, promising new indications, and strategic partnerships. Despite some challenges in the translational sector and policy headwinds, the company shows resilience with significant revenue growth and optimistic guidance. The Tempus partnership and expansion plans further support a positive outlook. While there are some uncertainties, the overall sentiment leans towards positive due to high growth rates, strategic positioning, and potential reimbursement achievements.
PSNL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
